Beth israel medical center
Brigham and womens hospital
Dana farber cancer institute
Hackensack university medical center
Jacobi medical center
Lenox hill hospital
Montefiore medical center
New york and presbyterian hospital
New york methodist hospital
North shore university hospital
Memorial Hospital For Cancer and Allied Diseases
Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.
Mol. Ther., Dec;16(12):2022-9 (2008)
Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine.
Cancer Immunol. Immunother., Sep;58(9):1397-405 (2009)
Biologics through chemistry: total synthesis of a proposed dual-acting vaccine targeting ovarian cancer by orchestration of oligosaccharide and polypeptide domains.
J. Am. Chem. Soc., Mar;131(11):4151-8 (2009)
From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine.
J. Am. Chem. Soc., Jul;131(26):9298-303 (2009)
Design and synthesis of potent Quillaja saponin vaccine adjuvants.
J. Am. Chem. Soc., Feb;132(6):1939-45 (2010)
Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins.
Vaccine., Jun;28(26):4260-7 (2010)
Impact of minimal tumor burden on antibody response to vaccination.
Cancer Immunol. Immunother., May;60(5):621-7 (2011)
Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.
Expert Rev Vaccines., Apr;10(4):463-70 (2011)
Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci.
Cancer Immunol. Immunother., Jan;61(1):9-18 (2012)
Synthesis and Preclinical Evaluation of QS-21 Variants Leading to Simplified Vaccine Adjuvants and Mechanistic Probes.
J. Am. Chem. Soc., Aug;134(32):13448-57 (2012)
Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity.
J. Immunol., May;174(9):5706-12 (2005)
Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity.
Vaccine., Sep;23(39):4727-33 (2005)
Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy.
Cancer Immunol. Immunother., Oct;54(10):1018-25 (2005)
Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates.
J. Am. Chem. Soc., Mar;128(8):2715-25 (2006)
Cancer vaccines targeting carbohydrate antigens.
Hum Vaccin., 2(3):137-43 (2006)
A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma.
Dig. Dis. Sci., Aug;52(8):1964-72 (2007)
Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.
Clin. Cancer Res., May;13(10):2977-85 (2007)
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
Clin. Cancer Res., Jul;13(14):4170-7 (2007)
Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma.
Mol. Ther., Nov;15(11):2044-50 (2007)
Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine.
Angew. Chem. Int. Ed. Engl., 47(34):6395-8 (2008)